Original Research May 20, 2024

A Combined Index Using the Mini-Mental State Examination and Lawton Index to Discriminate Between Clinical Dementia Rating Scores of 0.5 and 1: A Development and Validation Study

J Clin Psychiatry. 2024;85(2):23m15101

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

Abstract

Objective: To develop a combined index using cognitive function and instrumental activities of daily living (IADL) to discriminate between Clinical Dementia Rating (CDR) scores of 0.5 and 1 in the clinical setting, and to investigate its optimal cutoff values and internal and external validities.

Methods: We included outpatients aged 65–89 years with CDR scores of 0.5 or 1. The optimal cutoff values and internal validity were verified using Japanese memory clinic-based datasets between September 2010 and October 2021 [National Center for Geriatrics and Gerontology (NCGG) datasets]. Cognitive function and IADL were assessed using the Mini-Mental State Examination (MMSE) and Lawton Index (LI), respectively. The optimal cutoff values were defined using the Youden Index. To verify internal validity, sensitivity and specificity were calculated using stratified 5-fold cross-validation. To verify external validity, sensitivity and specificity of the optimal cutoff values were assessed in the Organized Registration for the Assessment of dementia on Nationwide General consortium toward Effective treatment (ORANGE) Registry dataset between July 2015 and March 2022, which has multicenter clinical data.

Results: A total of 800 (mean age, 77.53 years; men, 50.1%) and 1494 (mean age, 77.97 years; men, 43.3%) participants comprised the NCGG and ORANGE Registry datasets, respectively. The optimum cutoff values for men and women were determined as MMSE < 25 and LI < 5 and MMSE < 25 and LI < 8, respectively; such a combined index showed good discriminative performance in internal (sensitivity/specificity: men, 92.50/73.52; women, 88.57/65.65) and external validities (men, 81.43/77.62; women, 77.64/74.67).

Conclusion: The index developed is useful in discriminating between CDR scores of 0.5 and 1 and should be applicable to various settings, such as memory clinics and clinical research.

J Clin Psychiatry 2024;85(2):23m15101

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Risk Reduction of Cognitive Decline and Dementia [WHO Guidelines]. World Health Organization; 2019.
  2. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–e125. PubMed CrossRef
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.
  4. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227–2234. PubMed CrossRef
  5. Canevelli M, Grande G, Lacorte E, et al. Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and meta analysis. J Am Med Dir Assoc. 2016;17(10):943–948. PubMed CrossRef
  6. Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol. 2008;63(4):494–506. PubMed CrossRef
  7. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447–1455. PubMed CrossRef
  8. Farias ST, Mungas D, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151–1157. PubMed CrossRef
  9. Tsujimoto M, Suzuki K, Saji N, et al. Organized Registration for the Assessment of dementia by the Nationwide General consortium toward Effective treatment (ORANGE) registry: current status and perspectives of mild cognitive impairment. J Alzheimers Dis. 2022;88(4):1423–1433. PubMed CrossRef
  10. Ward A, Tardiff S, Dye C, et al. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013;3(1):320–332. PubMed CrossRef
  11. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–2263. PubMed CrossRef
  12. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. PubMed
  13. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572. PubMed CrossRef
  14. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–2414. PubMed CrossRef
  15. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. PubMed
  16. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef
  17. Tsoi KKF, Chan JYC, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450–1458. PubMed
  18. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016;2016(1):CD011145. PubMed CrossRef
  19. Arevalo-Rodriguez I, Smailagic N, Roqué-Figuls M, et al. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2021;7(7):CD010783. PubMed CrossRef
  20. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. PubMed CrossRef
  21. Jekel K, Damian M, Wattmo C, et al. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimers Res Ther. 2015;7(1):17. PubMed CrossRef
  22. Cloutier S, Chertkow H, Kergoat MJ, et al. Trajectories of decline on instrumental activities of daily living prior to dementia in persons with mild cognitive impairment. Int J Geriatr Psychiatry. 2021;36(2):314–323. PubMed CrossRef
  23. Saji N, Sakurai T, Suzuki K, et al; ORANGE investigators. ORANGE’s challenge: developing wide-ranging dementia research in Japan. Lancet Neurol. 2016;15(7):661–662. PubMed CrossRef
  24. Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer’s disease Cooperative Study experience. Neurology. 1997;48(6):1508–1510. PubMed CrossRef
  25. Burke WJ, Miller JP, Rubin EH, et al. Reliability of the Washington University clinical dementia rating. Arch Neurol. 1988;45(1):31–32. PubMed
  26. Berg L, McKeel DW Jr, Miller JP, et al. Neuropathological indexes of Alzheimer’s disease in demented and nondemented persons aged 80 years and older. Arch Neurol. 1993;50(4):349–358. PubMed CrossRef
  27. Morris JC, McKeel DW Jr, Storandt M, et al. Very mild Alzheimer’s disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991;41(4):469–478. PubMed CrossRef
  28. Morris JC, Storandt M, McKeel DW Jr, et al. Cerebral amyloid deposition and diffuse plaques in ‘normal’ aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology. 1996;46(3):707–719. PubMed
  29. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–186. PubMed
  30. Graf C. The Lawton instrumental activities of daily living scale. Am J Nurs. 2008;108(4):52–63; quiz 62–63. PubMed CrossRef
  31. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–65.
  32. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press; 2003.
  33. Anthony M, Holden SB. Cross-validation for binary classification by real-valued functions: theoretical analysis. COLT. 1998:218–229.
  34. Anguita D, Ghio A, Ridella S, et al. K-fold cross validation for error rate estimate in support vector machines. Proceedings of the 2009 International Conference on Data Mining; July 13–16, 2009; Las Vegas, NV.
  35. Awata S, Sugiyama M, Ito K, et al. Development of the dementia assessment sheet for community-based integrated care system. Geriatr Gerontol Int. 2016;16(suppl 1):123–131. PubMed CrossRef
  36. Reisberg B, Ferris SH, Anand R, et al. Functional staging of dementia of the Alzheimer type. Ann N Y Acad Sci. 1984;435:481–483.
  37. Holthoff VA, Ferris S, Ihl R, et al. Validation of the relevant outcome scale for Alzheimer’s disease: a novel multidomain assessment for daily medical practice. Alzheimers Res Ther. 2011;3(5):27. PubMed CrossRef